Pharmaceutical News

RSS

Researchers study how ketamine reduces side effects of ECT in people with severe depression

The largest trial into the use of Electroconvulsive Therapy in the UK in more than 30 years will look into how the use of the Class C drug ketamine might reduce the side effects of ECT for those being treated for severe depression.

2 May 2013

SSRIs associated with increased risk of bleeding, transfusion, readmission and death

Selective serotonin reuptake inhibitors (SSRIs) - among the most widely prescribed antidepressant medications - are associated with increased risk of bleeding, transfusion, hospital readmission and death when taken around the time of surgery, according to an analysis led by researchers at UC San Francisco and Baystate Medical Center in Springfield, Mass.

30 Apr 2013

Study: Biologic response modifying drugs can cause acute liver injury

A commonly used class of biologic response modifying drugs can cause acute liver injury with elevated liver enzymes, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

30 Apr 2013

Somalia launches pentavalent vaccine with support from GAVI, UNICEF, WHO

"Coinciding with World Immunization Week, the Somali government announced on 24 April its intention to vaccinate all children under the age of one with a new five-in-one vaccine, known as a pentavalent vaccine, funded by the GAVI Alliance, with [UNICEF] and the [WHO] as implementing partners," IRIN reports.

30 Apr 2013

Glide Pharma awarded contract from Pfenex Inc. to develop a solid formulation of recombinant anthrax vaccine

Glide Pharma® today announced the award of a sub-contract from Pfenex Inc. to develop a solid formulation containing the recombinant Protective Antigen (rPA) from Bacillus anthracis expressed in Pfēnex Expression Technology™ suitable for delivery with the Glide SDI® (solid dose injector). This approach will address two important logistical constraints of the currently available vaccine, namely, long term stability during storage and ease of administration.

30 Apr 2013

Continued work needed in vaccine development

Reflecting on World Immunization Week, April 21-28, Angeline Nanni, director of market access at Aeras, discusses the "remarkable results" of expanded immunization programs in a guest post on the Global Health Technologies Coalition's "Breakthroughs" blog.

30 Apr 2013

Kcentra gets FDA approval for adults with acute major bleeding

The U.S. Food and Drug Administration today approved Kcentra (Prothrombin Complex Concentrate, Human) for the urgent reversal of vitamin K antagonist anticoagulation in adults with acute major bleeding.

30 Apr 2013

Some GOP lawmakers are shifting focus from Medicare to the tax code

House Republican leaders began a series of meetings last week to sell this idea to their rank-and-file members. Also in Capitol Hill news, cancer clinics argue that Congress should have addressed the cuts they took as a result of sequestration before turning to the spending reductions' impact on air travel.

30 Apr 2013

FDA approves Octapharma USA's BLA for octaplex

The U.S. Food and Drug Administration has accepted Octapharma USA's Biological License Application for octaplex.

30 Apr 2013

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.

From Pfizer, Inc. 30 Apr 2013

Maruishi gains exclusive rights to develop, commercialize Cara Therapeutics' CR845 in Japan

Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara's lead analgesic drug candidate, CR845, for acute pain and uremic pruritus in Japan.

29 Apr 2013

Absorption Pharmaceuticals to obtain patent for Promescent medication

Absorption Pharmaceuticals announced today that the U.S. Patent and Trademark Office has indicated that it will grant a patent related to the use of its topical medication, Promescent, for premature ejaculation.

29 Apr 2013

Veloxis seeks EMA approval to market LCP-Tacro for kidney transplant patients

Veloxis Pharmaceuticals A/S today announced that it has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union.

29 Apr 2013

Oxford BioTherapeutics, Boehringer Ingelheim team up to discover novel cancer antibody targets

Oxford BioTherapeutics and Boehringer Ingelheim today announce a new alliance focused on the discovery of novel cancer antibody targets that OBT will identify with the help of its OGAP® discovery platform.

29 Apr 2013

Shin Poong to develop, market Almac Discovery's ALM201 in South Korea

Almac Discovery today announced the licensing of its novel anti-angiogenic peptide ALM201 to Shin Poong Pharmaceutical Company Ltd for clinical development and marketing in South Korea.

29 Apr 2013

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Avanir Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause.

29 Apr 2013